Galderma to launch calcitriol ointment in the US

[C#199200273:Galderma]has received US FDA approval for Vectical (calcitriol) 3μg/g ointment, for use in the treatment of mild-to-moderate plaque psoriasis in adults. It will be launched in the first quarter of this year. The product is already marketed in the UK (as Silkis) and elsewhere.

Galdermahas received US FDA approval for Vectical (calcitriol) 3μg/g ointment, for use in the treatment of mild-to-moderate plaque psoriasis in adults. It will be launched in the first quarter of this year. The product is already marketed in the UK (as Silkis) and elsewhere.

Vectical is the only calcitriol (vitamin D3) ointment available in the US, and Galderma claims that it is one of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

More from Therapeutic Category

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.